Oliver Luxxe Assets LLC Sells 46,892 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Oliver Luxxe Assets LLC decreased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 48.5% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 49,744 shares of the biopharmaceutical company’s stock after selling 46,892 shares during the period. Oliver Luxxe Assets LLC’s holdings in Catalyst Pharmaceuticals were worth $1,563,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in Catalyst Pharmaceuticals by 18.2% during the second quarter. GAMMA Investing LLC now owns 4,150 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 639 shares in the last quarter. Cim Investment Management Inc. acquired a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at $310,000. Bank of America Corp DE grew its holdings in shares of Catalyst Pharmaceuticals by 38.0% in the 1st quarter. Bank of America Corp DE now owns 3,036,546 shares of the biopharmaceutical company’s stock worth $75,185,000 after purchasing an additional 836,704 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Catalyst Pharmaceuticals by 16.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,998,875 shares of the biopharmaceutical company’s stock worth $49,520,000 after purchasing an additional 279,108 shares during the last quarter. Finally, Amundi increased its position in shares of Catalyst Pharmaceuticals by 68.4% during the 1st quarter. Amundi now owns 31,463 shares of the biopharmaceutical company’s stock worth $779,000 after purchasing an additional 12,778 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $31.49 on Monday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $32.56. The company’s 50-day moving average price is $31.43 and its two-hundred day moving average price is $27.94. The firm has a market cap of $3.86 billion, a P/E ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Oppenheimer downgraded shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Wall Street Zen cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $35.00 to $31.50 in a research report on Friday, May 8th. Finally, Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).